Convalescent Plasma To Limit Coronavirus Associated Complications: A Randomized Blinded Phase 2 Study Comparing The Efficacy And Safety Of Anti-Sars-Cov-2 Plasma To Placebo In Covid-19 Hospitalized Patients
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Covid-19
-
Age: Between 18 - 120 Years
-
Gender: Male or Female
-
Other Inclusion Criteria:
- Participants (or their legal/authorized representative) able to provide signed written informed consent
- Participants hospitalized for COVID-19 respiratory symptoms
- Participants hospitalized for less than 72 hours OR within day 3 to 7 from first signs of illness
- Participants are laboratory confirmed COVID-19
- On supplemental oxygen, non-invasive ventilation or high-flow oxygen (clinical status 3 or 4)
You may not be eligible for this study if the following are true:
-
- Participants who have received pooled immunoglobulin in past 30 days
- Participants with contraindication to transfusion or history of prior reactions to transfusion blood products
- Have invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)
- Participants with volume overload secondary to congestive heart failure or renal failure
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.